Back to the main directory
EarningsReview / Equity
- AXA: RDOS. 1S’24 Y VENTA DE AXA IM (ANÁLISIS BANCO SABADELL) by Sabadell
- INVEST SECURITIES - ORYZON GENOMICS : 10,8m€ disponibles à fin S1, visibilité jusqu'en 2025 - ACHAT, OC 4,8€ by Invest Securities
- INVEST SECURITIES - QIAGEN : Des résultats conformes, aucun signal d'achat - NEUTRE, OC 44€ by Invest Securities
- INVEST SECURITIES - ATOS : Une situation très dégradée fin S1 24 - VENTE, OC 0,01€ by Invest Securities
- AGBA - Termination of coverage by Edison Investment Research
- Sell-side meeting feedback: Hoping H2 gets busier by BNP Paribas Exane
- 百威亚太（1876 HK） by HSBC
- RWE / Calpine bid speculation by BNP Paribas Exane
- Hongkong Land (HKL SP) by HSBC
- Q2’24: small beat on margins, FY guidance tightened. Boring but good by BNP Paribas Exane
- Most Read Research - Week 25 July - 1 August 2024 by BNP Paribas Exane
- Guidance reiterated, India and China to support LT growth by BNP Paribas Exane
- Frontier 2Q24 Results by BNP Paribas Exane
- Mixed 2Q Print: EPS Beat, But More Pessimistic FY24 Outlook Will Be the Focus by BNP Paribas Exane
- Returning 42% of market cap over 24-26e remains the main appeal by BNP Paribas Exane
- DraftKings: off the call by BNP Paribas Exane
- EVolution: Sharp recovery in electrification by BNP Paribas Exane
- Q2’24 conference call feedback by BNP Paribas Exane
- ARPU Pressure by BNP Paribas Exane
- Signs of improvement by BNP Paribas Exane
- Engie 1H24 conference call key points & views by BNP Paribas Exane
- KNAUS TABBERT: coverage dropped by BNP Paribas Exane
- MEYER BURGER TECHNOLOGY: coverage dropped by BNP Paribas Exane
- Iberdrola acquires ENW by BNP Paribas Exane
- A missed opportunity; leverage yet to kick-in by BNP Paribas Exane